Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for r/r Malignant Tumors in Children
NCT04691349Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Beijing Boren Hospital autologous CAR-T therapy in cancer, sponsored by PersonGen BioTherapeutics. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
Beijing Boren Hospital autologous CAR-T therapy
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04691349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691349.